Atsena closes $150m in Series C round to progress gene therapy
Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of its lead gene therapy programme, ATSN-201, to treat X-linked retinoschisis (XLRS).
The funds are to be used to further develop its preclinical pipeline of therapies and broaden the usage of the company's adeno-associated virus with laterally spreading capsid.
Bain Capital's Life Sciences team headed the funding round, with contributions from new investor Wellington Management.
Current investors such as Lightstone Ventures, Abingworth, Foundation Fighting Blindness and Hatteras Venture Partners participated in this latest round.
XLRS is a condition that leads to blindness and is typically diagnosed in childhood.
Atsena's clinical portfolio has already gained US Food and Drug Administration (FDA) rare paediatric disease and orphan drug designations for both ATSN-101 and ATSN-201.
ATSN-101, which targets Leber Congenital Amaurosis type 1 (LCA1), has also been granted the regenerative medicine advanced therapy designation.
Updated outcomes from the ongoing Phase I/II LIGHTHOUSE trial of ATSN-201 are expected in late 2025.
The company also welcomed biopharmaceutical executive and scientist Dr Norbert Riedel to its board of directors.
For the Series C financing, Wedbush & Co acted as exclusive placement agent to the company, while Cooley provided legal counsel.
Atsena's investigational gene therapy, ATSN-101, has shown positive outcomes in a Phase I/II trial and is moving towards a pivotal trial in partnership with Nippon Shinyaku.
The company's pipeline leverages adeno-associated virus technology designed to address the challenges of inherited retinal conditions.
In March 2025, the company received fast track designation from the FDA for ATSN-201 to treat XLRS.
"Atsena closes $150m in Series C round to progress gene therapy" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
FDA approves YolTech's YOLT-101 for familial hypercholesterolemia
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for YOLT-101 to treat heterozygous familial hypercholesterolemia (HeFH). YOLT-101 is an in vivo base editing therapy designed to target proprotein convertase subtilisin/kexin type 9 (PCSK9). Its innovative approach lies in its potential to durably reduce blood low-density lipoprotein cholesterol (LDL-C) levels through a single-dose treatment. The technology behind YOLT-101 incorporates YolTech's adenine base editor, known as hpABE5, which consists of nCas and a new deaminase evolved from Hafnia paralvei. To deliver this therapeutic agent, the company employs an advanced lipid nanoparticle (LNP) delivery system. hpABE5 can perform precise A•T to G•C base conversions without inducing DNA double-strand breaks, thus minimising risks associated with chromosomal abnormalities and off-target effects. YolTech Therapeutics co-founder and CEO Yuxuan Wu stated: 'The FDA IND clearance marks a significant milestone for YolTech. In vivo gene editing represents a new generation of therapeutics — offering one-time, durable solutions for chronic and genetic diseases. 'We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases.' Currently under evaluation in an ongoing investigator-initiated trial (IIT), YOLT-101 has shown promising results with a favourable safety profile and substantial LDL-C–lowering effects. Familial hypercholesterolemia is a genetic disorder stemming from mutations affecting LDL metabolism-related genes such as LDLR, Apolipoprotein B (APOB) and PCSK9. Individuals suffering from FH typically experience elevated LDL-C levels, which contribute to a heightened risk of developing early-onset atherosclerotic cardiovascular diseases. "FDA approves YolTech's YOLT-101 for familial hypercholesterolemia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The SHIELD II trial is designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with the standard of care (SoC), which includes prophylactic systemic antibiotics, compared to the SoC alone arm in the prevention of post-abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The trial's primary endpoint is measured by the proportion of subjects with a surgical site infection or mortality for any reason within 30 days post-surgery. FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe, and Israel. D-PLEX100, PolyPid's lead product candidate, is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. The trial met the primary efficacy endpoint, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p<0.005). SHIELD II included three key secondary endpoints: The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p<0.005). The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p<0.005). The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1 score >20 in the D-PLEX100 plus SoC arm compared to the SoC alone arm (p<0.05). The ASEPSIS score is a clinical tool used to assess surgical wound infections objectively. The independent Data Safety Monitoring Board raised no safety concerns in SHIELD II. The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in early 2026, with a Marketing Authorization Application in the E.U. to follow shortly thereafter. Price Action: PYPD stock is trading higher by 12% to $3.66 at last check Monday. Read Next:Photo by ittawit21 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Scientific American
an hour ago
- Scientific American
Science-Backed Ways to Stay Healthy During Salmonella Outbreak in Eggs
3 min read To prevent salmonella food poisoning, refrigerate your eggs, cook them well, never eat them raw, and clean, clean, clean By edited by Dean Visser At least 79 people have been sickened by a salmonella outbreak linked to organic and cage-free eggs, distributed under various brand names across seven U.S. states. The eggs were processed by the August Egg Company in Hilmar, Calif., according to the Food and Drug Administration (FDA). On June 6, after FDA tests discovered the bacteria, the company issued a wide recall. The recall is just the latest in a string of callbacks linked to salmonella contamination. On June 7, TGD Cuts of Jessup, Md., recalled cucumber and salsa products, and on June 4 the FDA urged consumers to follow a recall that began in May of tomatoes packaged and shipped by various companies. What is salmonella, how can it make you sick, and how can you minimize your chances of getting it? Here are some basics. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. What Is Salmonella and How Does It Spread? Salmonella is a bacterium that thrives in the intestinal tract of certain animals, including chickens and cows—and humans. It is shed through feces. Like many foodborne pathogens, salmonella is often spread by improper cleaning or handling of raw food—including meat, eggs, seafood, vegetables, fruits and rice—at farms or factories. It is often associated with chicken and eggs, although past outbreaks have also been linked to peanut butter, raw pork and beef, cucumbers and even raw flour in cookie dough. When compromised products are shipped, stores and consumers may be unaware of the contamination until enough people start becoming sick and investigators trace the source back to specific food lots. The U.S. Centers for Disease Control and Prevention (CDC) estimates that 48 million Americans get sick from food each year. What Are the Symptoms of Salmonella Food Poisoning? You may begin to feel sick anywhere from eight to 72 hours after you are exposed. As the bacteria multiply, they can cause stomach cramps, diarrhea, vomiting and fever. Children under age five often account for a large percentage of cases in a Salmonella outbreak, and elderly people or those with weakened immune systems are at greater risk. In rare cases people develop joint pain or eye irritation. How Is It Treated? Infections often clear within three or four days, but if diarrhea lasts for more than two days, or body temperature rises above 102 degrees Fahrenheit, health officials urge you to see a doctor. Complications such as diarrhea can cause dehydration, so drink plenty of fluids. How Can I Minimize My Chances of Getting Salmonella? Contaminated food is the chief source, so never eat raw foods that can carry the bacteria. Refrigerate eggs or other susceptible foods at 40 degrees Fahrenheit or less. When preparing meals, use separate cutting boards and knives for suspect foods, and thoroughly wash them—as well as kitchen surfaces and your hands after prep. Microwave dishwashing sponges on high. Cook food to at least 160 degrees Fahrenheit (71 degrees Celsius). Should I Stop Kissing my own Chickens? Birds, hedgehogs, turtles, guinea pigs and even pet bearded dragons can carry Salmonella and make you sick through direct contact, according to a 2024 Scientific American story. The craze among homeowners that expanded during Covid to raise chickens in the backyard is also a culprit. Salmonella bacteria can linger on an animal's skin, so regardless of how cute you think your chickens are, try to not snuggle them or kiss them! Which evidently is a thing.
